Navigation Links
ImaRx to Report Corporate Updates and 4Q07 Financial Results
Date:3/20/2008

of 1995. Such statements include but are not limited those related to our efforts to grow the marketplace for urokinase, our intent to reduce our operating expenses associated with our SonoLysis development and our belief that we will allow the Company to explore additional therapeutic applications for the product. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include but are not limited to: sales of and demand for urokinase may decline, the FDA may not approve our future requests for urokinase lot releases or approval of expanded uses of urokinase beyond treatment of acute massive pulmonary emboli, we may not be able to complete definitive documentation with Microbix on the terms of our letter of intent, Microbix may not be able to perfect the manufacturing process or to secure approval from the FDA to manufacture urokinase, we may not be effective in our marketing efforts for urokinase, and we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 30, 2008, and the Company undertakes no duty to update this information. A more complete description of these risks can be found in the Company's filings with the Securities and Exchange Commission.

Contacts:

The Ruth Group

Sara Ephraim (investors)

646-536-7002

sephraim@theruthgroup.com

Jason Rando (media)

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
4. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
5. Vion Reports 2007 Fourth Quarter and Year-End Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
8. Warner Chilcott Reports the Death of Its Director James Andress
9. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Unigene Restates Policy on Analyst Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... be used for detailed studies of what happens on ... pharmaceuticals research, among other applications. A group of researchers ... artificial cell membranes form across a large number of ... between the interior of a cell and its surroundings ... a surface layer that holds the cell together and ...
(Date:9/2/2014)... 2014 Persistence Market Research ( ... Pharmaceutical, Biopharma and Life Sciences: North America ... membrane technology market for pharmaceutical, biopharma and life sciences is ... expected to grow at a CAGR of 9.1% from ... USD 10,886.0 million in 2019. Browse the ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... Dr. ... San Antonio and South Central Texas, , ... (PRWEB) June 15, 2010 -- For those looking for a trimmer physique without ... Zeltiq ™ Procedure, a new non-invasive body contouring procedure, at his practice - Advanced ...
... data from a retrospective cohort study showed that up to three quarters ... have a substantial adverse effect on major PD-related clinical and health economic ... Disease and Movement Disorders in Buenos Aires, Argentina ( June ... , "The ...
... leading publication on diversity and business, has recognized University Hospitals as a leader among ... , , ... Companies for Diversity based on results from an extensive questionnaire. This is the first ... , , ...
Cached Biology Technology:Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction 2Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 2New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 4Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation 2
(Date:9/2/2014)... perching birds, that migrate by night tend to fly ... reach their destinations. This seasonal difference in flight speed ... migratory flights, says researcher Cecilia Nilsson of Lund University ... Sociobiology . , Nilsson, in a group led ... measure over three years the speed by which birds ...
(Date:9/2/2014)... 2, 2014 Best-selling author Sam Kean stops by ... Megalodon, the 50-foot super shark that, despite what "Shark ... Learn all about it at http://youtu.be/KhFygIoW_MA . , ... of Madness, Love and the History of the World ... the Reactions treatment in a 10-episode video series produced ...
(Date:9/2/2014)... lithographic limestone is well known as a result ... area (for example, Archaeopteryx). Now, for the first ... French equivalent of these outcrops - discoveries which ... water treader. , Despite the abundance of fossils ... been obtained from the Late Kimmeridgian equivalents of ...
Breaking Biology News(10 mins):Migrating birds sprint in spring, but take things easy in autumn 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... Research to be presented at the Annual Meeting of the ... society for research into all aspects of eating and drinking ... their pregnancy were at risk to develop obesity and type ... that both prenatal stress exposure and passive stress coping style ...
... make a person more susceptible to the lung infection ... , the online open-access journal of the American Society ... (METH) significantly enhanced colonization of the lungs by ... and the time to death in mouse models. ...
... mind that is, your happiness affects your genes, ... from UCLA,s Cousins Center for Psychoneuroimmunology and the University of ... What they found is that different types ... People who have high levels of what ...
Cached Biology News:Methamphetamine increases susceptibility to deadly fungal infection 2Methamphetamine increases susceptibility to deadly fungal infection 3Be happy: Your genes may thank you for it 2Be happy: Your genes may thank you for it 3
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: